Ratings Alligator Bioscience AB London S.E.

Equities

0RK9

SE0000767188

Real-time Estimate Cboe Europe Other stock markets 07:08:54 2024-05-21 am EDT			5-day change	1st Jan Change
0.893 ^SEK	-64.40%		+123.96%	+303.28%

01:00pm	US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial	MT
May. 14	Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer	CI

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALLIGATOR BIOSCIENCE AB	+303.28%	63.23M	-
MODERNA, INC.	+41.79%	54.04B	B-
IQVIA HOLDINGS INC.	-0.56%	41.92B	B
LONZA GROUP AG	+47.07%	41.96B	A
CELLTRION, INC.	-7.20%	28.35B	C
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B	B
BIO-TECHNE CORPORATION	+6.92%	13B	B+
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B	B+
MEDPACE HOLDINGS, INC.	+29.60%	12.28B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes